Modeling of PET data in CNS drug discovery and development

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Journal of Pharmacokinetics and Pharmacodynamics

• Publication date

  2013-05-10

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1007/s10928-013-9320-6PMID 23660778
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Mapping Human Brain Fatty Acid Amide Hydrolase Activity with PET

  2013cited by this paper
• Non-linear mixed effects modelling of positron emission tomography data for simultaneous estimation of radioligand kinetics and occupancy in healthy volunteers

  2012cited by this paper
• New developments of dopaminergic imaging in Parkinson's disease.

  2012cited by this paper
• Combining PET Biodistribution and Equilibrium Dialysis Assays to Assess the Free Brain Concentration and BBB Transport of CNS Drugs

  2012cited by this paper
• Brain imaging in the study of Alzheimer's disease

  2012cited by this paper
• Compartmental modeling and simplified quantification of [11C]sertraline distribution in human brain

  2012cited by this paper
• Discovery and characterization of AZD9272 and AZD6538-Two novel mGluR5 negative allosteric modulators selected for clinical development.

  2012cited by this paper
• Monitoring therapeutic effects in Parkinson's disease by serial imaging of the nigrostriatal dopaminergic pathway.

  2011cited by this paper
• A Combined Accelerator Mass Spectrometry-Positron Emission Tomography Human Microdose Study with 14C- and 11C-Labelled Verapamil

  2011cited by this paper
• Dose-dependent binding of AZD3783 to brain 5-HT1B receptors in non-human primates and human subjects: a positron emission tomography study with [11C]AZ10419369

  2011cited by this paper
• Antipsychotic Occupancy of Dopamine Receptors in Schizophrenia

  2011cited by this paper
• Approaches using molecular imaging technology -- use of PET in clinical microdose studies.

  2011cited by this paper
• Quantitative Analysis of [11C]AZ10419369 Binding to 5-HT1B Receptors in Human Brain

  2011cited by this paper
• J Nucl Med

  2010cited by this paper
• Measuring Drug Occupancy in the Absence of a Reference Region: The Lassen Plot Re-Visited

  2010cited by this paper
• Molecular Imaging of the Dopamine Transporter

  2010cited by this paper
• The effect of plasma protein binding on in vivo efficacy: misconceptions in drug discovery

  2010cited by this paper
• P-Glycoprotein Function at the Blood–Brain Barrier in Humans Can Be Quantified with the Substrate Radiotracer 11C-N-Desmethyl-Loperamide

  2010cited by this paper
• Benzodiazepine Binding Site Occupancy by the Novel GABAA Receptor Subtype-Selective Drug 7-(1,1-Dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine (TPA023) in Rats, Primates, and Humans

  2010cited by this paper
• 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study.

  2010cited by this paper
• CENTER FOR DRUG EVALUATION AND RESEARCH

  2010cited by this paper
• Pharmacokinetics of fexofenadine: evaluation of a microdose and assessment of absolute oral bioavailability.

  2010cited by this paper
• Unbound Brain Concentration Determines Receptor Occupancy: A Correlation of Drug Concentration and Brain Serotonin and Dopamine Reuptake Transporter Occupancy for Eighteen Compounds in Rats

  2009cited by this paper
• Utility of small-animal positron emission tomographic imaging of rats for preclinical development of drugs acting on the serotonin transporter.

  2009cited by this paper
• Quantitative analysis of donepezil binding to acetylcholinesterase using positron emission tomography and [5-11C-methoxy]donepezil

  2009cited by this paper
• Assessment of MAO‐B Occupancy in the Brain With PET and [11C]‐L‐Deprenyl‐D2: A Dose‐Finding Study With a Novel MAO‐B Inhibitor, EVT 301

  2009cited by this paper
• PET radiotracers: crossing the blood-brain barrier and surviving metabolism.

  2009cited by this paper
• Target site occupancy: emerging generalizations from clinical and preclinical studies.

  2009cited by this paper
• Imaging of Cyclosporine Inhibition of P-Glycoprotein Activity Using 11C-Verapamil in the Brain: Studies of Healthy Humans

  2009cited by this paper
• The utility of microdosing over the past 5 years

  2008cited by this paper
• The utility of microdosing over the past 5 years

  2008cited by this paper
• Toward an improved prediction of human in vivo brain penetration

  2008cited by this paper
• PET kinetic analysis: error consideration of quantitative analysis in dynamic studies

  2008cited by this paper
• Tariquidar-Induced P-Glycoprotein Inhibition at the Rat Blood–Brain Barrier Studied with (R)-11C-Verapamil and PET

  2008cited by this paper
• Positon emission tomography: basic science and clinical practice

  2008cited by this paper
• In Vitro Methods for Estimating Unbound Drug Concentrations in the Brain Interstitial and Intracellular Fluids

  2007cited by this paper
• Consensus Nomenclature for in vivo Imaging of Reversibly Binding Radioligands

  2007cited by this paper
• On The Rate and Extent of Drug Delivery to the Brain

  2007cited by this paper
• A positron emission tomography microdosing study with a potential antiamyloid drug in healthy volunteers and patients with Alzheimer's disease

  2006cited by this paper
• TPA023 [7-(1,1-Dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine], an Agonist Selective for α2- and α3-Containing GABAA Receptors, Is a Nonsedating Anxiolytic in Rodents and Primates

  2006cited by this paper
• A comparison of recent parametric neuroreceptor mapping approaches based on measurements with the high affinity PET radioligands [11C]FLB 457 and [11C]WAY 100635

  2006cited by this paper
• Use of microdosing to predict pharmacokinetics at the therapeutic dose: Experience with 5 drugs

  2006cited by this paper
• Time Course of In Vivo 5-HTT Transporter Occupancy by Fluvoxamine

  2006cited by this paper
• Using positron emission tomography to facilitate CNS drug development.

  2006cited by this paper
• RELATIONSHIP BETWEEN EXPOSURE AND NONSPECIFIC BINDING OF THIRTY-THREE CENTRAL NERVOUS SYSTEM DRUGS IN MICE

  2005cited by this paper
• Tracer Kinetic Modeling in PET

  2005cited by this paper
• Using [11C]Diprenorphine to Image Opioid Receptor Occupancy by Methadone in Opioid Addiction: Clinical and Preclinical Studies

  2005cited by this paper
• Translational Neuroimaging: Positron Emission Tomography Studies of Monoamine Oxidase

  2005cited by this paper
• Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study.

  2004cited by this paper
• Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B

  2004cited by this paper
• Striatal and frontal cortex binding of 11-C-labelled clozapine visualized by positron emission tomography (PET) in drug-free schizophrenics and healthy volunteers

  2004cited by this paper
• Quantitative measurement of histamine H(1) receptors in human brains by PET and [11C]doxepin.

  2004cited by this paper
• Positron emission tomography microdosing: a new concept with application in tracer and early clinical drug development

  2003cited by this paper
• High levels of serotonin transporter occupancy with low-dose clomipramine in comparative occupancy study with fluvoxamine using positron emission tomography.

  2003cited by this paper
• Relationships between radiotracer properties and image quality in molecular imaging of the brain with positron emission tomography.

  2003cited by this paper
• Linearized Reference Tissue Parametric Imaging Methods: Application to [11C]DASB Positron Emission Tomography Studies of the Serotonin Transporter in Human Brain

  2003cited by this paper
• Effects of Buprenorphine Maintenance Dose on μ-Opioid Receptor Availability, Plasma Concentrations, and Antagonist Blockade in Heroin-Dependent Volunteers

  2003cited by this paper
• Positron emission tomographic analysis of dose-dependent NAD-299 binding to 5-hydroxytryptamine-1A receptors in the human brain

  2003cited by this paper
• Big physics, small doses: the use of AMS and PET in human microdosing of development drugs

  2003cited by this paper
• Pharmacokinetic Imaging

  2002cited by this paper
• Strategies to Improve Neuroreceptor Parameter Estimation by Linear Regression Analysis

  2002cited by this paper
• PET studies on the brain uptake and regional distribution of [11C]vinpocetine in human subjects

  2002cited by this paper
• A lipophilic thioflavin-T derivative for positron emission tomography (PET) imaging of amyloid in brain.

  2002cited by this paper
• Occupancy of brain serotonin transporters during treatment with paroxetine in patients with social phobia: a positron emission tomography study with [11C]McN 5652

  2002cited by this paper
• Models and methods for derivation of in vivo neuroreceptor parameters with PET and SPECT reversible radiotracers.

  2001cited by this paper
• Positron Emission Tomography Compartmental Models

  2001cited by this paper
• An introduction to PET and SPECT neuroreceptor quantification models.

  2001cited by this paper
• Effects of statistical noise on graphic analysis of PET neuroreceptor studies.

  2000cited by this paper
• Validation and Reproducibility of Measurement of 5-HT1A Receptor Parameters with [carbonyl-11C]WAY-100635 in Humans: Comparison of Arterial and Reference Tissue Input Functions

  2000cited by this paper
• Reproducibility of repeated measures of deuterium substituted [11C]L-deprenyl ([11C]L-deprenyl-D2) binding in the human brain.

  2000cited by this paper
• PET-Determination of Robalzotan (NAD-299) Induced 5-HT1A Receptor Occupancy in the Monkey Brain

  2000cited by this paper
• Changes of benzodiazepine receptors during chronic benzodiazepine administration in humans.

  1999cited by this paper
• PET imaging of central 5-HT2A receptors with carbon-11-MDL 100,907.

  1998cited by this paper
• Synthesis of [11C-methyl]-(-)-OSU6162, its regional brain distribution and some pharmacological effects of (-)-OSU6162 on the dopaminergic system studied in the rhesus monkey by positron emission tomography.

  1997cited by this paper
• PET neuroimaging with [11C]venlafaxine: serotonin uptake inhibition, biodistribution and binding in living pig brain.

  1997cited by this paper
• Simplified reference tissue model for PET receptor studies.

  1996cited by this paper
• Evaluation of cerebral pharmacokinetics of the novel antidepressant drug, BMS-181101, by positron emission tomography.

  1996cited by this paper
• Comparison of Methods for Analysis of Clinical [11C]Raclopride Studies

  1996cited by this paper
• Distribution Volume Ratios without Blood Sampling from Graphical Analysis of PET Data

  1996cited by this paper
• Oral administration of NNC 756 — a placebo controlled PET study of D1-dopamine receptor occupancy and pharmacodynamics in man

  1995cited by this paper
• Monoamine oxidase B (MAO B) inhibitor therapy in Parkinson's disease

  1993cited by this paper
• Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients.

  1993cited by this paper
• Compartmental Analysis of [11C]Flumazenil Kinetics for the Estimation of Ligand Transport Rate and Receptor Distribution Using Positron Emission Tomography

  1991cited by this paper
• Measurement of Cerebral Monoamine Oxidase B Activity Using L-[11C]Deprenyl and Dynamic Positron Emission Tomography

  1991cited by this paper
• Graphical Analysis of Reversible Radioligand Binding from Time—Activity Measurements Applied to [N-11C-Methyl]-(−)-Cocaine PET Studies in Human Subjects

  1990cited by this paper
• Cerebral blood flow, blood volume and oxygen utilization. Normal values and effect of age.

  1990cited by this paper
• D2 dopamine receptors in neuroleptic-naive schizophrenic patients. A positron emission tomography study with [11C]raclopride.

  1990cited by this paper
• Distribution of remoxipride to the human brain and central D2‐ dopamine receptor binding examined in vivo by PET

  1990cited by this paper
• Kinetic Analysis of Central [11C]Raclopride Binding to D2-Dopamine Receptors Studied by PET—A Comparison to the Equilibrium Analysis

  1989cited by this paper
• Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs.

  1988cited by this paper
• Mapping human brain monoamine oxidase A and B with 11C-labeled suicide inactivators and PET.

  1987cited by this paper
• Does mental activity change the oxidative metabolism of the brain?

  1987cited by this paper
• Quantitative analysis of D2 dopamine receptor binding in the living human brain by PET.

  1986cited by this paper
• Quantification of Neuroreceptors in the Living Human Brain. I. Irreversible Binding of Ligands

  1986cited by this paper
• Substituted benzamides as ligands for visualization of dopamine receptor binding in the human brain by positron emission tomography.

  1985cited by this paper
• A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography

  1984cited by this paper
• Kinetics of 11C-labeled opiates in the brain of rhesus monkeys.

  1984cited by this paper
• Brain regional pharmacokinetics of /sup 11/C-labeled diphenylhydantoin: positron emission tomography in humans

  1983cited by this paper
• Brain regional pharmacokinetics of 11‐labeled diphenylhydantoin

  1983cited by this paper
• Compartmental Analysis

  1970cited by this paper

• Dynamic positron emission tomography image reconstruction using spatiotemporal kernel method with deep image prior

  2025cites this paper
• Brain exposure of the mesenchymal-epithelial transition inhibitor savolitinib in nonhuman primates: A positron emission tomography study.

  2025cites this paper
• In vivo quantification of [11C]BIO-1819578 in non-human primates, a novel radioligand for O-GlcNAcase

  2025cites this paper
• Advances in neuroimaging in disorders of consciousness.

  2025cites this paper
• Antiviral treatment in schizophrenia: a randomized pilot PET study on the effects of valaciclovir on neuroinflammation

  2023cites this paper
• PET as a Translational Tool in Drug Development for Neuroscience Compounds

  2022cites this paper
• The dilemma of polypharmacy in psychosis: is it worth combining partial and full dopamine modulation?

  2022cites this paper
• Personalized medicine: Time for One person, one medicine

  2021cites this paper
• Application-specific nuclear medical in vivo imaging devices

  2021cites this paper
• Treating viruses in the brain: Perspectives from NeuroAIDS.

  2021cites this paper
• A PET study in healthy subjects of brain exposure of 11C-labelled osimertinib – A drug intended for treatment of brain metastases in non-small cell lung cancer

  2020cites this paper
• PET technology for drug development in psychiatry

  2020cites this paper
• Personalized medicine: An overview

  2019cites this paper
• Modeling and Simulation in the Translational Pharmacology of CNS Drugs

  2019cites this paper
• Simultaneous estimation of tracer kinetic model parameters using analytical and inverse approaches with a hybrid method

  2019cites this paper
• PET radioligands for the dopamine D1-receptor: Application in psychiatric disorders.

  2019cites this paper
• Design and Challenges of Radiopharmaceuticals.

  2019cites this paper
• Positron emission tomography : development, evaluation and application of quantification methods

  2018cites this paper
• Clinical Pharmacokinetics and Pharmacodynamics of Drugs in the Central Nervous System

  2018cites this paper
• Imaging of Microglial Activation in Alzheimer's Disease by [11C]PBR28 PET.

  2018cites this paper
• Positron Emission Tomography Studies of the Glial Cell Marker Translocator Protein in Patients With Psychosis: A Meta-analysis Using Individual Participant Data

  2018cites this paper
• Pharmacokinetics–pharmacodynamics of antifungal agents in the central nervous system

  2018cites this paper
• Biomarkers for Alzheimer’s Disease Drug Development

  2018cites this paper
• Accuracy and reliability of [11C]PBR28 specific binding estimated without the use of a reference region

  2018cites this paper
• Brain Theranostics and Radiotheranostics: Exosomes and Graphenes In Vivo as Novel Brain Theranostics

  2018cites this paper
• Lower levels of the glial cell marker TSPO in drug-naive first-episode psychosis patients as measured using PET and [11C]PBR28

  2017cites this paper
• PET microdosing of CNS drugs

  2017cites this paper
• Personalizing NSCLC therapy by characterizing tumors using TKI-PET and immuno-PET.

  2017cites this paper
• Basics and Advances of Quantitative PET Imaging

  2017cites this paper
• Inhibiting Kinases in the CNS

  2017cites this paper
• PET studies of the glial cell marker TSPO in psychosis patients - a meta-analysis using individual participant data

  2017cites this paper
• Tumor characterization using radiolabeled anti-cancer drugs in NSCLC patients

  2017cites this paper
• Neuroinflammation in Neurodegenerative Disorders—a Review

  2017cites this paper
• An inverse method for tracer kinetic modelling with positron emission tomography (PET) using hybrid method

  2016cites this paper
• The Impact of PGC-1α on Engineered Muscle Tissue and the Use of PET-Scan for Cell Tracking and Functional Analyses

  2016cites this paper
• Considerations in the Development of Reversibly Binding PET Radioligands for Brain Imaging.

  2016cites this paper
• Improved simultaneous estimation of tracer kinetic models with artificial immune network based optimization method.

  2016cites this paper
• Discovery and Evaluation of Clinical Candidate AZD3759, a Potent, Oral Active, Central Nervous System-Penetrant, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor.

  2015cites this paper
• Fast and efficient (18) F-labeling by [(18) f]fluorophenylazocarboxylic esters.

  2014cites this paper
• Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Pharmacy 188 Nonlinear Mixed Effects Methods for Improved Estimation of Receptor Occupancy in PET Studies

  2014cites this paper
• Automated radiochemical synthesis and biodistribution of [¹¹C]l-α-acetylmethadol ([¹¹C]LAAM).

  2014cites this paper
• Non-Invasive Imaging Modalities for Clinical Investigation in Regenerative Medicine

  2014influential citation
• A Philosophy for CNS Radiotracer Design

  2014cites this paper
• Methodological advancements in data analysis and quantitative performance of positron emission tomography

  2013cites this paper